최초입력 2025.04.22 10:51:34
South Korea’s SillaJen saw its shares surge nearly 23 percent on Tuesday morning after the company announced that the U.S. Food and Drug Administration (FDA) approved a change in its clinical trial protocol.
The stock was trading at 3,000 won ($2.11) as of 9:17 a.m., up 22.95 percent from the previous day’s close. The stock opened with a 23.36 percent gain and jumped as high as 24.18 percent at one point.
SillaJen disclosed on Monday that the FDA had approved an amendment to its investigational new drug (IND) application, allowing it to expand its trial of the anticancer drug BAL0891 to include patients with acute myeloid leukemia (AML).
The company also said it had agreed to acquire substance and biomarker patents related to BAL0891 from Dutch biotech firm Crossfire Oncology B.V. Analysts say the move could significantly reduce milestone-related licensing costs going forward.
SillaJen shares closed at 3,170 won.
[ⓒ 매일경제 & mk.co.kr, 무단 전재, 재배포 및 AI학습 이용 금지]